Wechselwirkungen · Sycrest
Sycrest 5 mg sublingual tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-212323 · Präparat HOS-154872
Potential for other medicinal products to affect Sycrest Asenapine is cleared primarily through direct glucuronidation by UGT1A4 and oxidative metabolism by cytochrome P450 isoenzymes (predominantly CYP1A2). The potential effects of inhibitors and an inducer of several of these enzyme pathways on asenapine pharmacokinetics were studied, specifically fluvoxamine (CYP1A2 inhibitor), paroxetine (CYP2D6 inhibitor), imipramine (CYP1A2/2C19/3A4 inhibitor), cimetidine (CYP3A4/2D6/1A2 inhibitor), carbamazepine (CYP3A4/1A2 inducer) and valproate (UGT inhibitor). Except for fluvoxamine, none of the interacting medicinal products resulted in clinically relevant alterations in asenapine pharmacokinetics.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paroxetine (HOS-086246) valproate (HOS-085955) cimetidine (HOS-085835) carbamazepine (HOS-085618) imipramine (HOS-085907) fluvoxamine (HOS-085908)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-25T11:45:00Z · SHA-256 7184cfbc7f9e05ce1e99b04023c799d93f0bd912f125aaadedecf6de2f657133 · Passage fa1747f9e06dabbc49038e6c82decb2253f50fb55a364dc607cdf126b6e9f55d · Zeichen 264–965 im Abschnitt